Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICEF15 cell implantation for fecal incontinence
2024-518243-38-00Phase 3Authorised
- Sponsor
- Innovacell
- Start
- Jan 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in fecal incontinence (FI) comparing ICEF15 with Placebo (2 arms). Primary endpoint: Change in frequency of fecal incontinence episodes. Planned start Jan 2025; status: authorised.
02
Drugs
ICEF 15
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on 2024-518243-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518243-38-00.